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Clinical PerspectiveWhat Is New?To understand the potential impact of new drug therapies for hyperkalemia, it is important to assess the true burden of hyperkalemia among people with heart failure (HF).In a population‐based cohort study including 31 649 patients with first hospital‐diagnosed HF, almost 4 in 10 patients developed hyperkalemia (potassium \>5.0 mmol/L) over 2.2 years.The risk of developing hyperkalemia was strongly associated with degree of reduced kidney function and spironolactone use, and recurrent hyperkalemia was frequent.Compared with matched patients with HF without hyperkalemia, events of hyperkalemia were associated with severe clinical outcomes, including arrhythmias, intensive care admission, and death.What Are the Clinical Implications?Among patients with HF in everyday clinical care, attention to the substantial risk of hyperkalemia is prudent.Efforts to prevent and normalize hyperkalemia should be directed to patients with HF, chronic kidney disease, and diabetes mellitus, and to those who use spironolactone.Our data support the need for regular potassium measurement to identify patients with HF at risk of serious clinical outcomes and death.

 {#jah33183-sec-0008}

Heart failure (HF) affects \>37 million adults worldwide and is a leading cause of hospitalizations and death.[1](#jah33183-bib-0001){ref-type="ref"}, [2](#jah33183-bib-0002){ref-type="ref"} Despite improvements in HF therapy and prognosis,[3](#jah33183-bib-0003){ref-type="ref"} hospitalizations with HF remain frequent, and comorbidities, including diabetes mellitus and renal disease, have become more common.[2](#jah33183-bib-0002){ref-type="ref"}, [3](#jah33183-bib-0003){ref-type="ref"}, [4](#jah33183-bib-0004){ref-type="ref"}, [5](#jah33183-bib-0005){ref-type="ref"}

Hyperkalemia, usually defined as blood potassium level \>5.0 mmol/L, is a concern in patients with HF in everyday clinical practice and can be a life‐threatening condition.[6](#jah33183-bib-0006){ref-type="ref"}, [7](#jah33183-bib-0007){ref-type="ref"} Hyperkalemia with high potassium levels (eg, \>6.0 mmol/L) may lead to cardiac arrhythmias and death,[8](#jah33183-bib-0008){ref-type="ref"} but even potassium levels of \>5.0 mmol/L have been associated with increased mortality in patients with acute‐care hospital admission[6](#jah33183-bib-0006){ref-type="ref"} and in patients with HF.[9](#jah33183-bib-0009){ref-type="ref"}, [10](#jah33183-bib-0010){ref-type="ref"}

Knowledge is scarce on the occurrence of hyperkalemia and associated outcomes in patients with HF in the real‐world setting.[11](#jah33183-bib-0011){ref-type="ref"}, [12](#jah33183-bib-0012){ref-type="ref"} Patients with kidney disease have an increased risk of hyperkalemia,[7](#jah33183-bib-0007){ref-type="ref"} and a dynamic association between heart and kidney dysfunction has been described in the cardiorenal syndrome,[13](#jah33183-bib-0013){ref-type="ref"} with evidence of chronic kidney disease in more than half of patients with HF.[14](#jah33183-bib-0014){ref-type="ref"} Moreover, several drugs commonly used for treating HF may lead to hyperkalemia[15](#jah33183-bib-0015){ref-type="ref"} by interfering with renal potassium excretion, including angiotensin‐converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and potassium‐sparing diuretics, such as spironolactone and eplerenone.[11](#jah33183-bib-0011){ref-type="ref"}, [16](#jah33183-bib-0016){ref-type="ref"}

To understand the potential impact of new drug therapies for hyperkalemia,[8](#jah33183-bib-0008){ref-type="ref"}, [17](#jah33183-bib-0017){ref-type="ref"} it is important to assess the true burden of hyperkalemia among people with HF and to assess associated patient characteristics, current treatment practices, and clinical outcomes in real‐world settings. We, therefore, undertook a large population‐based cohort study in Denmark to examine occurrence, risk factors, and outcomes of hyperkalemia in patients with HF.

Methods {#jah33183-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results. According to Danish legislation, researchers may apply for the data at the Danish Health Data Authority.

Setting {#jah33183-sec-0010}
-------

This cohort study was conducted in northern Denmark, by using routine care laboratory test results from both primary and hospital care for the entire region\'s population (1 851 496 residents \[33% of Denmark\'s population\] by the end of 2012).[18](#jah33183-bib-0018){ref-type="ref"} The laboratory data were linked using the Civil Personal Registration number with data from the Danish National Patient Registry, which contains dates of admission and discharge (including emergency department and outpatient clinic visits) and procedures.[19](#jah33183-bib-0019){ref-type="ref"} Furthermore, data on drugs were retrieved from the Aarhus University Prescription Database, which holds records of type of drug, date of dispensing, and quantity on all prescribed drugs dispensed from Danish pharmacies in northern Denmark.[20](#jah33183-bib-0020){ref-type="ref"}

Patients With HF and Covariates {#jah33183-sec-0011}
-------------------------------

From the source population of all individuals living in northern Denmark, we identified a cohort of individuals with a first‐time inpatient hospital admission with a primary or secondary discharge diagnosis of HF between 2000 and 2012. The HF diagnosis has a positive predictive value of ≈80% in the Danish National Patient Registry.[21](#jah33183-bib-0021){ref-type="ref"} On the basis of the lowest estimated glomerular filtration rate (eGFR) measured up to and including the date of first HF admission (or presence of dialysis), patients were classified into kidney disease stage 1 and 2, eGFR ≥60 mL/min per 1.73 m^2^; stage 3A, eGFR of 45 to 59 mL/min per 1.73 m^2^; stage 3B, eGFR of 30 to 44 mL/min per 1.73 m^2^; stage 4, eGFR of 15 to 29 mL/min per 1.73 m^2^; stage 5, eGFR of \<15 mL/min per 1.73 m^2^; and dialysis.[22](#jah33183-bib-0022){ref-type="ref"} Baseline characteristics at time of the first HF admission were based on dispensed drugs from pharmacies within the past 12 months and on diagnoses and procedures recorded in the National Patient Registry any time up to and including the date of HF discharge. Patients were followed up for hyperkalemia events from the time of the first HF hospital admission until migration, death, or end of follow‐up.

All codes and variable algorithms used in the study are provided in Table [S1](#jah33183-sup-0001){ref-type="supplementary-material"}.

Statistical Analysis {#jah33183-sec-0012}
--------------------

### Incidence of hyperkalemia {#jah33183-sec-0013}

An incident episode of hyperkalemia was defined as an elevated blood potassium level \>5.0 mmol/L not preceded by a prior episode of elevated potassium within the previous month. Incidence of hyperkalemia events with cut points potassium \>5.5 mmol/L and potassium \>6.0 mmol/L was examined separately. Incidence rates of a first hyperkalemia event per 1000 person‐years were calculated. Cumulative incidence function curves were constructed, and risks (cumulative incidence proportions) of developing hyperkalemia within 1 and 3 years were estimated. The risk of developing a second, third, and fourth hyperkalemia event was also described.

### Risk factors at the time of hyperkalemia {#jah33183-sec-0014}

To examine risk factors before the hyperkalemia/index date, one comparison patient without hyperkalemia was matched to each corresponding patient with hyperkalemia on the index date, according to sex, age, calendar time, and time since first HF admission. Prevalence ratios (PRs) for the association of specified risk factors were calculated.

### Outcomes associated with hyperkalemia {#jah33183-sec-0015}

In a before‐after analysis among patients with HF who all had experienced hyperkalemia, the cumulative incidence proportion ratios (risk ratios \[RRs\]) of experiencing each individual clinical outcome during the 6 months after, versus 6 months before, the hyperkalemia event date were calculated, accounting for competing risk of death within 6 months after the hyperkalemia date.

Second, a matched cohort design with Cox regression was used to estimate the hazard ratio (HR) of clinical outcomes 6 months after the hyperkalemia/index date in patients with hyperkalemia versus age, sex, and HF duration matched comparisons without hyperkalemia. Factors potentially associated with both hyperkalemia risk and outcomes were adjusted for, including intensity of HF treatment regimen and number of acute HF hospitalizations 6 months before the hyperkalemia/index date as marker of HF severity, eGFR category, Charlson Comorbidity Index score, presence of specific hyperkalemia risk factors (diabetes mellitus/chronic kidney disease/hypertension), and use of ACEis/ARBs, spironolactone, or potassium supplements.

Additional and Sensitivity Analyses {#jah33183-sec-0016}
-----------------------------------

Although potassium tests were generally frequent in the HF cohort (mean, 23 tests; median, 15 tests; interquartile range, 5--31 tests per patient during the observation period), bias by indication for blood testing may be a concern (ie, sicker patients possibly receiving more frequent blood testing with higher likelihood of hyperkalemia being detected). Therefore, the analyses were repeated using a randomly selected set of 5 potassium tests per patient among patients with HF with at least 5 tests the year after HF. Second, to study hyperkalemia impact in a subcohort more likely to have chronic HF, and thus be more closely followed up, patients who were alive at 6 months after HF discharge had an echocardiography performed and were treated with both ARBs or ACEis and β blocker up to this date were separately examined. Third, as an alternative method to account for remaining unmeasured confounding when comparing outcomes in patients with and without hyperkalemia with HF, the ratio of the 2 matched HRs observed after versus before the hyperkalemia/index date (ie, the prior event rate ratio adjusted rate ratio) was estimated.[23](#jah33183-bib-0023){ref-type="ref"} This method is based on the assumption that differences in outcomes between hyperkalemia‐exposed and matched hyperkalemia‐unexposed patients present already *before* experiencing hyperkalemia reflect the combined effect of remaining unmeasured confounders, independent of any effect of hyperkalemia. Fourth, to exclude reverse causality (ie, acute‐care hospitalization outcomes, such as intensive care unit admission, leading to secondary hyperkalemia, versus being a consequence of hyperkalemia), outcomes were also examined separately for hyperkalemia detected on the first admission date of any hospitalization. Fifth, analyses were stratified by initial HF diagnosis being primary (first‐listed) versus secondary diagnosis. Sixth, we evaluated outcomes separately for elevated potassium detected on dates on which patients were hospitalized versus out of hospital, and we repeated the outcome analyses separately in patients with \<10 potassium tests versus patients with ≥10 tests before the hyperkalemia event. Finally, the influence of potential unmeasured confounding was quantified by means of a rule‐out approach.[24](#jah33183-bib-0024){ref-type="ref"} We estimated how strongly an unmeasured binary confounder would need to be associated with hyperkalemia and outcomes to fully explain our findings, and we illustrated this association graphically.

The study was approved by the Danish Data Protection Agency. The study was purely registry based and did not involve any contact with patients or interventions; therefore, according to Danish legislation, no informed consent was required.

Results {#jah33183-sec-0017}
=======

Baseline Characteristics {#jah33183-sec-0018}
------------------------

Overall, the analysis comprised 31 649 individuals with a first incident hospital record of HF in northern Denmark from 2000 to 2012. Median age was high, at 78 (interquartile range, 69--85) years, and 47% were women (Table [1](#jah33183-tbl-0001){ref-type="table"}). Diagnosed cardiomyopathy at time of first HF diagnosis was relatively rare (4%), whereas 14% had known valvular heart disease, 21% had prior MI, 40% had any ischemic heart disease, 35% had atrial fibrillation, and 62% had hypertension. In total, two thirds (68%) of the patients had a history of hospital‐diagnosed comorbidities included in the Charlson Comorbidity Index on admission; 19% had diabetes mellitus, 41% had chronic kidney disease, and 18% had chronic pulmonary disease. At baseline before first admission, 24% of the patients were treated with ACEis, 11% were treated with ARBs, 31% were treated with βblockers, 11% were treated with spironolactone, and 30% were treated with potassium supplements. Of the patients, 57% had been examined with echocardiography. Three months after initial HF diagnoses, proportions with echocardiography and receiving drug treatment had increased considerably in our cohort, as expected (for subpopulation with chronic HF, see later).

###### 

Baseline Characteristics Among Patients With First Hospital‐Diagnosed HF Stratified by eGFR Category and Subsequent Incidence of Hyperkalemia

  Characteristics                                                   eGFR Category, mL/min per 1.73 m^2^ [a](#jah33183-note-0003){ref-type="fn"}   Total                                                                                                                 
  ----------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ----------------- -------------------
  No. of patients with HF (row %)                                   7679 (24.3)                                                                   6931 (21.9)         5800 (18.3)         3707 (11.7)         1166 (3.7)          298 (0.9)           6068 (19.2)       31 649 (100)
  Female sex                                                        2602 (33.9)                                                                   3241 (46.8)         3198 (55.1)         2016 (54.4)         612 (52.5)          93 (31.2)           3047 (50.2)       14 809 (46.8)
  Age, median (quartiles), y                                        70 (60.2--79.0)                                                               78 (69.7--84.3)     82 (74.6--87.0)     83 (76.1--87.7)     81 (73.5--86.4)     70 (60.3--78.6)     79 (71.5--85.4)   78 (69.1--84.9)
  Echocardiography performed before/at first HF admission           5021 (65.4)                                                                   4222 (60.9)         3381 (58.3)         2262 (61.0)         735 (63.0)          223 (74.8)          2281 (37.6)       18 125 (57.3)
  HF as primary diagnosis                                           2977 (38.8)                                                                   2586 (37.3)         2109 (36.4)         1277 (34.4)         412 (35.3)          124 (41.6)          2423 (39.9)       11 908 (37.6)
  Conditions underlying HF[b](#jah33183-note-0004){ref-type="fn"}                                                                                                                                                                                                       
  Cardiomyopathy                                                    494 (6.4)                                                                     312 (4.5)           195 (3.4)           124 (3.3)           24 (2.1)            12 (4.0)            180 (3.0)         1341 (4.2)
  Valvular heart disease                                            867 (11.3)                                                                    947 (13.7)          931 (16.1)          629 (17.0)          189 (16.2)          51 (17.1)           648 (10.7)        4262 (13.5)
  Myocardial infarction                                             1506 (19.6)                                                                   1513 (21.8)         1406 (24.2)         1034 (27.9)         324 (27.8)          99 (33.2)           905 (14.9)        6787 (21.4)
  Ischemic heart disease                                            2780 (36.2)                                                                   2819 (40.7)         2540 (43.8)         1810 (48.8)         530 (45.5)          162 (54.4)          2093 (34.5)       12 734 (40.2)
  Atrial fibrillation                                               2393 (31.2)                                                                   2585 (37.3)         2243 (38.7)         1426 (38.5)         402 (34.5)          81 (27.2)           1964 (32.4)       11 094 (35.1)
  Other comorbidities                                                                                                                                                                                                                                                   
  Diabetes mellitus                                                 1222 (15.9)                                                                   1162 (16.8)         1225 (21.1)         1007 (27.2)         360 (30.9)          107 (35.9)          993 (16.4)        6076 (19.2)
  Chronic kidney disease[c](#jah33183-note-0005){ref-type="fn"}     59 (0.8)                                                                      3524 (50.8)         4579 (78.9)         3224 (87.0)         1068 (91.6)         298 (100)           243 (4.0)         12 995 (41.1)
  Hypertension                                                      3942 (51.3)                                                                   4399 (63.5)         4195 (72.3)         2968 (80.1)         955 (81.9)          270 (90.6)          2852 (47.0)       19 581 (61.9)
  Peripheral vascular disease                                       566 (7.4)                                                                     721 (10.4)          768 (13.2)          656 (17.7)          254 (21.8)          99 (33.2)           609 (10.0)        3673 (11.6)
  Cerebrovascular disease                                           948 (12.3)                                                                    1155 (16.7)         1229 (21.2)         865 (23.3)          294 (25.2)          58 (19.5)           940 (15.5)        5489 (17.3)
  Chronic pulmonary disease                                         1315 (17.1)                                                                   1301 (18.8)         1156 (19.9)         761 (20.5)          205 (17.6)          56 (18.8)           1044 (17.2)       5838 (18.4)
  Peptic ulcer disease                                              514 (6.7)                                                                     582 (8.4)           641 (11.1)          514 (13.9)          178 (15.3)          54 (18.1)           546 (9.0)         3029 (9.6)
  Any malignant disease                                             963 (12.5)                                                                    1052 (15.2)         1035 (17.8)         751 (20.3)          246 (21.1)          66 (22.1)           665 (11.0)        4778 (15.1)
  Alcoholism‐related disorders                                      775 (10.1)                                                                    438 (6.3)           372 (6.4)           311 (8.4)           121 (10.4)          43 (14.4)           360 (5.9)         2420 (7.6)
  Medical obesity                                                   577 (7.5)                                                                     433 (6.2)           370 (6.4)           311 (8.4)           124 (10.6)          22 (7.4)            322 (5.3)         2159 (6.8)
  Drug treatment before first HF diagnosis                                                                                                                                                                                                                              
  ACEis overall                                                     1588 (20.7)                                                                   1625 (23.4)         1516 (26.1)         1109 (29.9)         353 (30.3)          93 (31.2)           1146 (18.9)       7430 (23.5)
  Ramipril                                                          650 (8.5)                                                                     652 (9.4)           570 (9.8)           440 (11.9)          122 (10.5)          39 (13.1)           241 (4.0)         2714 (8.6)
  Enalapril                                                         437 (5.7)                                                                     450 (6.5)           440 (7.6)           324 (8.7)           109 (9.3)           33 (11.1)           284 (4.7)         2077 (6.6)
  Other ACEis                                                       422 (5.5)                                                                     426 (6.1)           422 (7.3)           289 (7.8)           92 (7.9)            20 (6.7)            600 (9.9)         2271 (7.2)
  ACEi/diuretic combination                                         156 (2.0)                                                                     175 (2.5)           160 (2.8)           118 (3.2)           51 (4.4)            4 (1.3)             67 (1.1)          731 (2.3)
  ARBs overall                                                      647 (8.4)                                                                     724 (10.4)          756 (13.0)          595 (16.1)          215 (18.4)          70 (23.5)           396 (6.5)         3403 (10.8)
  Losartan                                                          271 (3.5)                                                                     302 (4.4)           308 (5.3)           241 (6.5)           95 (8.1)            27 (9.1)            193 (3.2)         1437 (4.5)
  Candesartan                                                       114 (1.5)                                                                     123 (1.8)           120 (2.1)           93 (2.5)            40 (3.4)            32 (10.7)           57 (0.9)          579 (1.8)
  Other ARBs                                                        93 (1.2)                                                                      115 (1.7)           119 (2.1)           83 (2.2)            30 (2.6)            11 (3.7)            61 (1.0)          512 (1.6)
  ARB/diuretic combination                                          235 (3.1)                                                                     232 (3.3)           252 (4.3)           223 (6.0)           63 (5.4)            6 (2.0)             118 (1.9)         1129 (3.6)
  β Blockers                                                        2046 (26.6)                                                                   2110 (30.4)         1945 (33.5)         1500 (40.5)         491 (42.1)          175 (58.7)          1475 (24.3)       9742 (30.8)
  Spironolactone                                                    522 (6.8)                                                                     595 (8.6)           759 (13.1)          618 (16.7)          195 (16.7)          7 (2.3)             755 (12.4)        3451 (10.9)
  Potassium supplements                                             1447 (18.8)                                                                   1852 (26.7)         2011 (34.7)         1557 (42.0)         457 (39.2)          62 (20.8)           2151 (35.4)       9537 (30.1)
  Loop diuretics                                                    1890 (24.6)                                                                   2332 (33.6)         2525 (43.5)         2187 (59.0)         734 (63.0)          182 (61.1)          2634 (43.4)       12 484 (39.4)
  NSAIDs                                                            1685 (21.9)                                                                   1466 (21.2)         1221 (21.1)         904 (24.4)          282 (24.2)          28 (9.4)            1490 (24.6)       7076 (22.4)
  Trimethoprim                                                      91 (1.2)                                                                      140 (2.0)           176 (3.0)           168 (4.5)           68 (5.8)            3 (1.0)             152 (2.5)         798 (2.5)
  Macrolides                                                        911 (11.9)                                                                    808 (11.7)          627 (10.8)          463 (12.5)          136 (11.7)          41 (13.8)           788 (13.0)        3774 (11.9)
  Hyperkalemia event \>5.0 mmol/L                                                                                                                                                                                                                                       
  Total with a first hyperkalemia event                             2706 (35.2)                                                                   2884 (41.6)         2823 (48.7)         1985 (53.5)         641 (55.0)          167 (56.0)          1134 (18.7)       12 340 (39.0)
  Time to event in patients with event, median, y                   0.53                                                                          0.43                0.19                0.08                0.07                0.17                3.91              0.34
  Potassium tests before first event, median                        9                                                                             9                   7                   5                   6                   8                   7                 8
  1‐y Cumulative incidence, % (95% CI)                              21.3 (20.1--22.4)                                                             26.1 (24.7--27.5)   35.0 (33.1--36.9)   43.6 (40.8--46.5)   48.1 (42.6--53.6)   47.7 (36.8--58.5)   2.8 (2.4--3.2)    25.2 (24.5--25.8)
  Incidence rate per 1000 person‐years                              125.7                                                                         189.3               325.5               569.8               786.2               827.4               58.5              178.0
  Hyperkalemia event \>5.5 mmol/L                                                                                                                                                                                                                                       
  Total with a first hyperkalemia event                             1135 (14.8)                                                                   1365 (19.7)         1472 (25.4)         1177 (31.8)         433 (37.1)          129 (43.3)          513 (8.5)         6224 (19.7)
  Time to event in patients with event, median, y                   1.13                                                                          0.87                0.47                0.16                0.08                0.25                4.29              0.61
  Potassium tests before first event, median                        16                                                                            13                  11                  8                   8                   11                  12                11
  1‐y Cumulative incidence, % (95% CI)                              7.1 (6.5--7.7)                                                                10.3 (9.5--11.1)    15.7 (14.6--16.8)   23.3 (21.5--25.1)   30.4 (26.6--34.2)   32.6 (24.7--40.4)   1.0 (0.8--1.3)    11.2 (10.8--11.6)
  Incidence rate per 1000 person‐years                              42.7                                                                          68.5                123.9               234.4               367.9               465.9               24.4              72.5
  Hyperkalemia event \>6.0 mmol/L                                                                                                                                                                                                                                       
  Total with a first hyperkalemia event                             491 (6.4)                                                                     593 (8.6)           688 (11.9)          603 (16.3)          233 (20.0)          81 (27.2)           245 (4.0)         2934 (9.3)
  Time to event in patients with event, median, y                   1.50                                                                          1.30                0.70                0.22                0.09                0.38                4.48              0.84
  Potassium tests before first event, median                        20                                                                            16                  13                  9                   8                   14                  17                14
  1‐y Cumulative incidence, % (95% CI)                              2.7 (2.3--3.1)                                                                3.8 (3.4--4.3)      6.7 (6.0--7.4)      11.7 (10.5--12.9)   15.7 (13.2--18.2)   18.5 (13.1--23.9)   0.4 (0.2--0.6)    4.9 (4.7--5.2)
  Incidence rate per 1000 person‐years                              17.5                                                                          27.3                51.4                102.1               161.2               213.8               11.4              31.7

Data are given as number (percentage) unless otherwise indicated. Percentages are based on the first row. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor II blocker; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure.

Patients categorized according to lowest measured eGFR before or on admission date with HF; presence of dialysis overrules any eGFR measurement result.

As present at the time of HF diagnosis.

Manifest chronic kidney disease was defined on the date of the second of 2 measurements \>90 days apart of a creatinine value corresponding to an eGFR \<60 mL/min per 1.73 m^2^ or on the first date of a hospital diagnosis.

Incidence of Hyperkalemia {#jah33183-sec-0019}
-------------------------

During 69 318 person‐years of follow‐up (mean, 2.2 years), 39% (n=12 340) of the patients experienced a first hyperkalemia event with potassium of \>5.0 mmol/L, resulting in an incidence rate of 178 per 1000 person‐years (Table [1](#jah33183-tbl-0001){ref-type="table"}), increasing with age and comorbidity (Table [S2](#jah33183-sup-0001){ref-type="supplementary-material"}). The cumulative risk of hyperkalemia was 25% during the first year and 32% within 3 years after HF diagnosis. Among patients with stage 3A, 3B, 4, or 5 kidney disease, or dialysis, 26%, 35%, 44%, 48%, and 48% experienced hyperkalemia within the first year. Median time to first hyperkalemia event in those who experienced an event was 0.34 years; 7787 events (63%) were hospital diagnosed.

The panels of Figure [1](#jah33183-fig-0001){ref-type="fig"} each display cumulative incidence curves of first event of potassium \>5.0 mmol/L, potassium \>5.5 mmol/L, or potassium \>6.0 mmol/L by decreasing kidney function. Almost half (43%) of all patients with a first hyperkalemia event had a second event, whereas risks of experiencing a third event or fourth event were 54% and 60%, respectively, with successively shorter time between the episodes (Figure [2](#jah33183-fig-0002){ref-type="fig"}).

![Cumulative incidence curves for first occurrence of potassium \>5.0 mmol/L, potassium \>5.5 mmol/L, or potassium \>6.0 mmol/L in patients with first hospital diagnosed heart failure, according to estimated glomerular filtration rate (eGFR) category.](JAH3-7-e008912-g001){#jah33183-fig-0001}

![Proportions and median follow‐up time for patients with heart failure (HF) experiencing recurrent hyperkalemia (HK) events.](JAH3-7-e008912-g002){#jah33183-fig-0002}

Risk Factors of Hyperkalemia {#jah33183-sec-0020}
----------------------------

Patients who developed hyperkalemia had similar underlying HF causes as those who did not develop hyperkalemia, but most comorbidities were more common in those with hyperkalemia (Table [2](#jah33183-tbl-0002){ref-type="table"}). Use of spironolactone was also increased, whereas use of other hyperkalemia‐associated medications at the time of hyperkalemia was not higher. There was an association between hyperkalemia and decreasing eGFR values (eGFR 30--44 mL/min per 1.73 m^2^: PR, 1.38; 95% confidence interval \[CI\], 1.33--1.45; eGFR 15--29 mL/min per 1.73 m^2^: PR, 2.05; 95% CI, 1.94--2.17; eGFR \<15 mL/min per 1.73 m^2^: PR, 2.83; 95% CI, 2.49--3.21), and with presence of chronic kidney disease overall (PR, 1.46; 95% CI, 1.43−1.49), diabetes mellitus (PR, 1.38; 95% CI, 1.32−1.45), peripheral vascular disease (PR, 1.34; 95% CI, 1.30−1.43), and use of spironolactone (PR, 1.48; 95% CI, 1.42−1.54). The relative importance of risk factors increased, by higher potassium level (Table [S3](#jah33183-sup-0001){ref-type="supplementary-material"}).

###### 

Prevalence of Risk Factors at Time of Hyperkalemia/Index Date Among Patients With HF With Hyperkalemia and Matched Comparisons Without Hyperkalemia

  Variable                                                                            Patients With HF With First Hyperkalemia \>5.0 mmol/L   Matched HF Comparisons Without Hyperkalemia[a](#jah33183-note-0007){ref-type="fn"}   Matched PR (95% CI)
  ----------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------
  No. of patients                                                                     12 340 (100)                                            12 151 (100)                                                                         ...
  Female sex                                                                          5670 (45.9)                                             5581 (45.9)                                                                          ...
  Age, median (quartiles), y                                                          78.6 (70.2--85.1)                                       78.7 (70.6--85.0)                                                                    ...
  Potassium tests 6 mo before hyperkalemia/index date, median (quartiles)             5.0 (2.0--11.0)                                         2.0 (0.0--6.0)                                                                       ...
  Acute HF hospitalizations 6 mo before hyperkalemia/index date, median (quartiles)   0.0 (0.0--1.0)                                          0.0 (0.0--1.0)                                                                       ...
  Conditions underlying HF[b](#jah33183-note-0008){ref-type="fn"}                                                                                                                                                                  
  Cardiomyopathy                                                                      925 (7.5)                                               806 (6.6)                                                                            1.13 (1.03--1.24)
  Valvular heart disease                                                              2182 (17.7)                                             1754 (14.4)                                                                          1.22 (1.16--1.30)
  Myocardial infarction                                                               3551 (28.8)                                             3236 (26.6)                                                                          1.08 (1.0--1.13)
  Any ischemic heart disease                                                          5796 (47.0)                                             5268 (43.4)                                                                          1.08 (1.05--1.11)
  Atrial fibrillation                                                                 4843 (39.2)                                             4679 (38.5)                                                                          1.02 (0.99--1.05)
  Lowest eGFR measured before hyperkalemia/index date                                                                                                                                                                              
  No values \<60 mL/min per 1.73 m^2^                                                 1636 (13.3)                                             2530 (20.8)                                                                          0.64 (0.60--0.67)
  eGFR 45--59 mL/min per 1.73 m^2^                                                    2502 (20.3)                                             3062 (25.2)                                                                          0.80 (0.77--0.84)
  eGFR 30--44 mL/min per 1.73 m^2^                                                    3702 (30.0)                                             2633 (21.7)                                                                          1.38 (1.33--1.45)
  eGFR 15--29 mL/min per 1.73 m^2^                                                    3119 (25.3)                                             1498 (12.3)                                                                          2.05 (1.94--2.17)
  eGFR \<15 mL/min per 1.73 m^2^                                                      896 (7.3)                                               312 (2.6)                                                                            2.83 (2.49--3.21)
  Dialysis                                                                            235 (1.9)                                               73 (0.6)                                                                             3.17 (2.44--4.12)
  No eGFR measurement recorded                                                        250 (2.0)                                               2043 (16.8)                                                                          0.12 (0.11--0.14)
  Selected predefined risk factors for hyperkalemia                                                                                                                                                                                
  Diabetes mellitus                                                                   3425 (27.8)                                             2440 (20.1)                                                                          1.38 (1.32--1.45)
  Chronic kidney disease[c](#jah33183-note-0009){ref-type="fn"}                       8139 (66.0)                                             5489 (45.2)                                                                          1.46 (1.43--1.49)
  Hypertension                                                                        10 180 (82.5)                                           9454 (77.8)                                                                          1.06 (1.05--1.07)
  Other comorbidities                                                                                                                                                                                                              
  Peripheral vascular disease                                                         2050 (16.6)                                             1503 (12.4)                                                                          1.34 (1.3--1.43)
  Cerebrovascular disease                                                             2483 (20.1)                                             2333 (19.2)                                                                          1.05 (1.0--1.10)
  Chronic pulmonary disease                                                           3327 (27.0)                                             2797 (23.0)                                                                          1.17 (1.1--1.22)
  Peptic ulcer disease                                                                1483 (12.0)                                             1214 (10.0)                                                                          1.20 (1.1--1.29)
  Any malignant disease                                                               2143 (17.4)                                             1881 (15.5)                                                                          1.12 (1.06--1.19)
  Alcoholism‐related disorders                                                        1193 (9.7)                                              937 (7.7)                                                                            1.25 (1.16--1.36)
  Medical obesity                                                                     1110 (9.0)                                              881 (7.3)                                                                            1.24 (1.14--1.35)
  Use of hyperkalemia‐associated medications                                                                                                                                                                                       
  ACEis overall                                                                       5580 (45.2)                                             5113 (42.1)                                                                          1.07 (1.04--1.11)
  Ramipril                                                                            2700 (21.9)                                             2337 (19.2)                                                                          1.14 (1.08--1.20)
  Enalapril                                                                           1284 (10.4)                                             1059 (8.7)                                                                           1.19 (1.10--1.29)
  Other ACEis                                                                         1624 (13.2)                                             1717 (14.1)                                                                          0.93 (0.87--0.99)
  ACEi/diuretic combination                                                           306 (2.5)                                               299 (2.5)                                                                            1.01 (0.86--1.18)
  ARBs overall                                                                        1779 (14.4)                                             1663 (13.7)                                                                          1.05 (0.99--1.12)
  Losartan                                                                            775 (6.3)                                               794 (6.5)                                                                            0.96 (0.87--1.06)
  Candesartan                                                                         414 (3.4)                                               297 (2.4)                                                                            1.37 (1.19--1.59)
  Other ARBs                                                                          308 (2.5)                                               252 (2.1)                                                                            1.20 (1.02--1.42)
  ARB/diuretic combination                                                            425 (3.4)                                               468 (3.9)                                                                            0.89 (0.79--1.02)
  Spironolactone                                                                      4125 (33.4)                                             2753 (22.7)                                                                          1.48 (1.42--1.54)
  Potassium supplements                                                               6229 (50.5)                                             6100 (50.2)                                                                          1.01 (0.98--1.03)
  Loop diuretics                                                                      8130 (65.9)                                             7683 (63.2)                                                                          1.04 (1.02--1.06)
  NSAIDs                                                                              2727 (22.1)                                             2705 (22.3)                                                                          0.99 (0.95--1.04)
  Trimethoprim                                                                        428 (3.5)                                               371 (3.1)                                                                            1.14 (0.99--1.30)
  Macrolides                                                                          1598 (12.9)                                             1413 (11.6)                                                                          1.11 (1.04--1.19)

Data are given as number (percentage) unless otherwise indicated. Percentages are based on the first row. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor II blocker; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; NSAIDS, nonsteroidal anti‐inflammatory drugs; PR, prevalence ratio.

HF comparison patients without hyperkalemia matched on age, sex, and duration of HF on the hyperkalemia/index date.

As present at the time of HF diagnosis.

Manifest chronic kidney disease was defined on the date of the second of 2 measurements \>90 days apart of a creatinine value corresponding to an eGFR \<60 mL/min per 1.73 m^2^ or on the first date of a hospital diagnosis of chronic kidney disease (see Table [S1](#jah33183-sup-0001){ref-type="supplementary-material"} for codes).

Clinical Outcomes of Hyperkalemia {#jah33183-sec-0021}
---------------------------------

In patients with hyperkalemia, the incidence proportion with any acute‐care hospitalization was 53% within 6 months before the hyperkalemia event, increasing to 74% 6 months after the hyperkalemia event, corresponding to a competing risk of death adjusted before‐after RR of 1.41 (95% CI, 1.38−1.44) (Figure [3](#jah33183-fig-0003){ref-type="fig"}). The risk for any cardiac hospital diagnosis increased from 44% to 61% (before‐after RR, 1.46; 95% CI, 1.43−1.50), for HF hospitalization from 33% to 43% (RR, 1.42; 95% CI, 1.37--1.46), for ventricular arrhythmias from 2.4% to 3.6% (RR, 1.90; 95% CI, 1.65−2.18), for intensive care unit admissions from 3.3% to 14.9% (RR, 5.29; 95% CI, 4.77−5.86), for ventilator therapy from 1.3% to 8.0% (RR, 7.17; 95% CI, 6.10--8.43), and for cardiac arrest from 0.2% to 1.3% (RR, 9.89; 95% CI, 6.17--15.84). Six‐month mortality after hyperkalemia was 36%. Among patients who survived after hyperkalemia, discontinuation of hyperkalemia‐associated drugs was rarely seen (eg, adjusted RRs were 1.02, 1.11, and 1.10 for ARBs, ACEis, and spironolactone, yet 0.90 for potassium supplements) (Figure [3](#jah33183-fig-0003){ref-type="fig"}). Reductions in average defined daily doses were rarely observed in those who continued drugs (eg, for ACEis, 2.0 and 1.9 defined daily doses before and after; for ARBs, 1.4 defined daily doses both before and after; data not shown).

![Clinical outcomes before and after hyperkalemia (HK). Dark gray bars show outcomes 6 months before and after the HK date in patients with heart failure with HK. Corresponding after vs before risk ratios are shown, adjusted for competing risk of death after HK. Light gray bars show outcomes in age‐, sex‐, and heart failure duration--matched patients with heart failure without HK as a point of comparison. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor II blocker; CI, confidence interval; ICU, intensive care unit.](JAH3-7-e008912-g003){#jah33183-fig-0003}

When compared with matched patients without hyperkalemia, and adjusting for the prior event increased HRs, 6‐month HRs for clinical outcomes after the index date were higher in patients with hyperkalemia: 2.3‐fold higher for any acute‐care hospitalization, 2.3‐fold higher for ventricular arrhythmias, 4.4‐fold higher for intensive care unit admission, and 7.3‐fold higher for cardiac arrest. The 6‐month adjusted HR of death was 3.39 (95% CI, 3.19--3.61) (Table [3](#jah33183-tbl-0003){ref-type="table"}). Outcome RRs were generally higher for more pronounced potassium elevations (Table [S4](#jah33183-sup-0001){ref-type="supplementary-material"}).

###### 

HRs for Clinical Outcomes 6 Months After Hyperkalemia Versus Fully Matched Comparisons Without Hyperkalemia

  Outcome                               Patients With HF With First Hyperkalemia \>5.0 mmol/L   Matched HF Comparisons Without Hyperkalemia[a](#jah33183-note-0011){ref-type="fn"}   Fully Adjusted HR (95% CI)[b](#jah33183-note-0012){ref-type="fn"}   Prior Event Rate Ratio Adjusted HR (95% CI)[c](#jah33183-note-0013){ref-type="fn"}
  ------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------------------------
  Any hospital outpatient contact       7760 (3204.49)                                          6444 (1717.40)                                                                       1.64 (1.58--1.70)                                                   1.39 (1.34--1.46)
  Any acute‐care hospitalization        9100 (4499.29)                                          5101 (1261.17)                                                                       2.75 (2.65--2.85)                                                   2.26 (2.17--2.35)
  Any non--acute‐care hospitalization   2786 (778.41)                                           1913 (381.40)                                                                        1.93 (1.81--2.06)                                                   1.65 (1.53--1.78)
  Any cardiac diagnosis                 7492 (3017.17)                                          4198 (980.49)                                                                        2.47 (2.37--2.58)                                                   2.19 (2.09--2.29)
  Ventricular arrhythmia                450 (104.85)                                            230 (41.67)                                                                          2.27 (1.91--2.69)                                                   2.33 (1.88--2.88)
  Cardiac arrest                        156 (35.42)                                             41 (7.35)                                                                            5.34 (3.70--7.73)                                                   7.30 (3.55--16.01)
  Dialysis procedure                    223 (51.06)                                             61 (10.95)                                                                           1.75 (1.30--2.35)                                                   1.18 (0.85--1.60)
  Ventilator treatment                  990 (233.90)                                            185 (33.38)                                                                          6.80 (5.77--8.02)                                                   4.46 (3.29--5.86)
  ICU admission                         1837 (460.02)                                           459 (83.93)                                                                          5.12 (4.60--5.71)                                                   4.42 (3.80--5.29)
  HF readmission                        5309 (1718.65)                                          3147 (692.21)                                                                        2.15 (2.05--2.26)                                                   1.96 (1.88--2.05)
  ACEi prescription                     4430 (1572.70)                                          4863 (1311.79)                                                                       1.05 (1.01--1.10)                                                   0.99 (0.95--1.02)
  ARB prescription                      1223 (305.03)                                           1406 (276.36)                                                                        1.00 (0.92--1.09)                                                   1.03 (0.97--1.09)
  Spironolactone prescription           3182 (943.22)                                           2876 (625.89)                                                                        1.07 (1.02--1.13)                                                   0.84 (0.81--0.88)
  Potassium supplement prescription     4109 (1326.70)                                          5919 (1713.53)                                                                       0.81 (0.78--0.84)                                                   0.75 (0.72--0.78)
  Death                                 4457 (1006.59)                                          1542 (276.03)                                                                        3.39 (3.19--3.61)                                                   --

ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor II blocker; CI, confidence interval; HF, heart failure; HR, hazard ratio; ICU, intensive care unit.

HF comparisons without hyperkalemia individually matched to patients with HF with hyperkalemia on age, sex, and HF duration (see Statistical Analysis section).

Adjusted for age, sex, and HF duration by matched design and, by Cox regression analyses, for HF treatment regimen, number of acute HF hospitalizations 6 months before the hyperkalemia/index date, estimated glomerular filtration rate category, Charlson Comorbidity Index score, presence of diabetes mellitus/chronic kidney disease/hypertension, use of ACEis/ARBs, spironolactone, or potassium supplements.

The prior event rate ratio adjusted HR is the ratio of the 2 age, sex, and HF duration matched rate ratios observed 6 months after vs 6 months before the hyperkalemia/index date. (see Additional and Sensitivity Analyses section).

When restricted to the subcohort of patients with chronic HF, incidences of hyperkalemia increased less steeply during early follow‐up, but total hyperkalemia incidence rates were close to those in all patients with HF, with similar risk factors, whereas outcome RRs after hyperkalemia were less high (Tables [S5](#jah33183-sup-0001){ref-type="supplementary-material"} through [S7](#jah33183-sup-0001){ref-type="supplementary-material"}). When repeating analyses using 5 random potassium tests per person (Tables [S8](#jah33183-sup-0001){ref-type="supplementary-material"} through [S10](#jah33183-sup-0001){ref-type="supplementary-material"}), incidences of hyperkalemia were modestly reduced versus the main analysis (1‐year cumulative incidence decreased from 25.2% to 20.9%), risk factor estimates were similar, and outcome associations with hyperkalemia were weaker (eg, adjusted HR for acute‐care hospitalization, 1.99 \[main analysis, 2.75\]; adjusted HR for intensive care unit, 3.18 \[main analysis, 5.12)\]. When repeating analyses for those with initial HF as primary diagnosis, all results remained robust and were similar to the main analysis (Tables [S11](#jah33183-sup-0001){ref-type="supplementary-material"} through [S13](#jah33183-sup-0001){ref-type="supplementary-material"}). The associations between hyperkalemia and clinical outcomes were generally stronger when potassium was measured on in‐hospital days than out‐of‐hospital days (Tables [S14](#jah33183-sup-0001){ref-type="supplementary-material"} and [S15](#jah33183-sup-0001){ref-type="supplementary-material"}) and in patients with ≥10 potassium tests than in patients with \<10 potassium tests (Tables [S16](#jah33183-sup-0001){ref-type="supplementary-material"} and [S17](#jah33183-sup-0001){ref-type="supplementary-material"}). Finally, when quantifying the influence of potential unmeasured confounding (Figure [S1](#jah33183-sup-0001){ref-type="supplementary-material"}), we found that to explain an adjusted HR of ≈2.0 for acute‐care hospitalizations associated with hyperkalemia, a confounder that was 4 times more frequent among patients with hyperkalemia, compared with patients without hyperkalemia, would need to increase the hazard of acute‐care hospitalization by a factor of ≥10 to explain our findings fully (if no increased hazard actually existed).

Discussion {#jah33183-sec-0022}
==========

This population‐based cohort study provides a longitudinal overview of hyperkalemia occurrence, risk factors, and prognosis in patients with incident HF in Denmark over 13 years. Approximately 1 in 4 patients with incident hospital‐diagnosed HF developed hyperkalemia within the first year, whereas risk of hyperkalemia was even higher in patients with both HF and kidney disease. Recurrent hyperkalemia episodes were common. Individuals treated with spironolactone and those with diabetes mellitus and renal failure were at particularly increased risk. Hyperkalemia was strongly associated with adverse clinical outcomes in patients with HF, including ≈1.4‐fold higher risk of acute‐care and cardiac hospitalizations compared with the time period before hyperkalemia in the same patients, and ≈2.2‐fold higher rates of these outcomes and 3.2‐fold higher mortality compared with matched patients with HF without hyperkalemia.

Our findings are consistent with previous studies, but they suggest that the real‐world burden of hyperkalemia is even greater in patients with cardiorenal syndrome than anticipated.[25](#jah33183-bib-0025){ref-type="ref"} In the PARADIGM‐HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study, ≈15% in both treatment groups developed hyperkalemia within a median follow‐up of 27 months,[26](#jah33183-bib-0026){ref-type="ref"} whereas the risks of hyperkalemia in patients with HF were generally lower in a UK observational study[11](#jah33183-bib-0011){ref-type="ref"} and in several other randomized controlled trials.[27](#jah33183-bib-0027){ref-type="ref"} The risk of hyperkalemia was substantially higher in our study, which likely mirrors a different universal healthcare system with inclusion of all hospital contacts with HF, including also elderly, comorbid, and frail patients. Our findings indicate that the true real‐world burden of hyperkalemia is even greater than anticipated and highlight that patients with the cardiorenal syndrome are at particular high risk of hyperkalemia. In our current analysis, risk factors for hyperkalemia included chronic kidney disease, diabetes mellitus, and use of spironolactone, as corroborated by others' findings.[11](#jah33183-bib-0011){ref-type="ref"}, [12](#jah33183-bib-0012){ref-type="ref"}, [28](#jah33183-bib-0028){ref-type="ref"}, [29](#jah33183-bib-0029){ref-type="ref"}, [30](#jah33183-bib-0030){ref-type="ref"}

Our study adds to the literature on the prognostic impact of hyperkalemia among patients with HF. In a Danish cohort study of 2596 patients with myocardial infarction receiving loop diuretics (as a proxy for HF), all levels of elevated potassium, including slightly increased levels, predicted death from any cause (4.6--5.0 mmol/L: adjusted HR, 1.6; 5.1--5.5 mmol/L: adjusted HR, 2; \>5.5 mmol/L, adjusted HR, 5.6).[9](#jah33183-bib-0009){ref-type="ref"} Similarly, among 7788 patients with chronic HF in the Digitalis Investigation Group trial, mild hyperkalemia was associated with ≈15% increased mortality.[10](#jah33183-bib-0010){ref-type="ref"} However, mild hyperkalemia was not associated with cardiovascular or HF mortality or all‐cause or cardiovascular hospitalization. Among 3900 patients admitted with acute HF in the Patients Hospitalized with acute heart failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) and Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) trials, admission potassium levels of \>5.0 mEq/L versus normal potassium level were associated with a 2.36‐fold increased risk of death after 6 months.[30](#jah33183-bib-0030){ref-type="ref"} However, the association weakened considerably and became nonsignificant after multivariate adjustment for kidney dysfunction and other predictors. Comparison with our study is difficult because we examined hyperkalemia as a risk factor for being acutely hospitalized with different conditions, and for mortality as a separate outcome, rather than studying hyperkalemia as a prognostic factor among patients already acutely hospitalized with HF. Our findings extend current knowledge, suggesting that elevated potassium levels \>5.0 mmol/L may be associated with higher risk of cardiovascular hospitalizations and arrhythmias in patients with HF.

Although most current guidelines for HF recommend clinicians to consider stopping or reducing dose of ACEi/ARB or potassium‐sparing diuretics if potassium increases \>5.5 mmol/L,[15](#jah33183-bib-0015){ref-type="ref"} the proportion of users and the dosing of these drugs remained broadly unchanged after the initial hyperkalemia event. Potential explanations may include that some patients had potassium levels \<5.5 mmol/L or that some patients had transient elevated potassium levels not requiring cessation of treatment.

Any conclusions on causal mechanisms in our study should be made with caution. Hyperkalemia measured in association with acute‐care hospitalization may be a consequence of the condition leading to hospital contact (eg, infection, dehydration, or deteriorating kidney function), rather than causing the hospitalization. The exact order of events in the pathophysiological pathway leading to a acute‐care hospitalization is difficult to disentangle. It is impossible to determine in our registry‐based study, in which patients with hyperkalemia did *not* have any bearing on the acute‐care hospitalization and its course. However, the findings that outcome RRs were higher for more severe versus mild hyperkalemia events and that specific diagnoses, such as cardiac arrhythmia or cardiac arrest, were associated with high levels of potassium argue for a causal association.

Interestingly, the results of our analysis were consistent in a subset of patients with chronic HF receiving ACEi/ARB blockade and β blockers in whom ≈40% had chronic kidney disease (eGFR \<45 mL/min per 1.73 m^2^). This indicates that careful surveillance of potassium levels is important in patients with chronic HF, and future studies should address the role for novel prevention and treatment strategies.

Our real‐world observational study of the burden of hyperkalemia in patients with HF has both strengths and weaknesses. The Danish public healthcare system permitted a population‐based design with inclusion of all patients with incident HF and subsequent incident hyperkalemia in a well‐defined geographical region. This largely eliminated some of the selection problems encountered in clinic‐based or health insurance--based observational studies.

The validity of our findings depends on the completeness and quality of registry data. We relied on potassium and other tests ordered in everyday clinical practice (ie, by medical indication for measurement). Sicker patients may have had a higher likelihood of any hyperkalemia being detected because of higher frequency of testing, leading to potential overestimation of hyperkalemia incidence and possibly also its clinical consequences. However, our patients all had in‐hospital--diagnosed HF and are all likely to receive regular blood tests in a universally covering healthcare system, as demonstrated by the high average number of potassium tests observed. Moreover, we were able to control for several HF severity markers and other prognostic predictors. Our registry data did not allow for further adjustment for potential differences in left ventricular ejection fraction or New York Heart Association class.

Hyperkalemia incidence and adverse outcomes decreased modestly but remained high when only examining several random potassium tests per person. Moreover, associations between hyperkalemia and clinical outcomes were generally stronger, not weaker, when focusing on people with many potassium tests, arguing against potassium elevations being casual findings. The less severe outcome observed with hyperkalemia measured on out‐of‐hospital versus in‐hospital days is more difficult to interpret. Although this might suggest that "hyperkalemia in primary care" is a less severe condition, our analysis immanently selects for patients who are not sick enough to be hospitalized on the hyperkalemia index day (unfortunately, we had only data on hyperkalemia test dates, not on the caregiver requesting the test). Finally, methods for blood potassium analysis have not been uniform in all laboratories over the entire study period, including both serum‐ and plasma‐based tests over the years, which is an inevitable limitation. False‐positive hyperkalemia was presumably rare because all laboratories took various precautions to avoid falsely elevated potassium values, which included nonreporting of potassium values in the presence of hemolysis.

The validity of medical diagnoses and disease algorithms that we used in our study has been documented as high.[21](#jah33183-bib-0021){ref-type="ref"} Data on diagnoses set by general practitioners were not available, only general practitioner prescribed drugs, and our data thus may have been incomplete for less severe lifestyle‐treated conditions followed up in primary care. Because all reimbursed prescriptions have to be redeemed at pharmacies in Denmark, obtaining drugs from other sources is unlikely. Nonetheless, prescription redemption is only a marker of consumption of any drug and noncompliance is possible.

Conclusion {#jah33183-sec-0023}
==========

In this study, a substantial proportion of patients with HF developed hyperkalemia, and recurrences were common. In particular, those with kidney disease and those treated with spironolactone were at high risk. Hyperkalemia was associated with severe clinical outcomes and death in patients with HF.
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